Lampard Inquiry Signals Possible Early Safety Recommendations as Essex Mental Health Hearings Resume

The chair of a major public inquiry examining mental health deaths in Essex has indicated that interim recommendations could be issued within weeks if evidence reveals risks to patient safety that cannot wait for the inquiry's final report.

Baroness Kate Lampard, who leads the Lampard Inquiry, said she would act on any issues that "might pose an urgent risk to patient safety" by making recommendations before the full findings are published. The inquiry is investigating the deaths of more than 2,000 people who died while receiving care from Essex mental health services between 2000 and the end of 2023. The scale of the death toll makes it one of the most significant examinations of mental health provision ever undertaken in England.

Further evidence hearings are scheduled to begin on 5 October, after which Baroness Lampard will decide whether early recommendations are necessary. She confirmed that any interim recommendations would likely concentrate on two areas of inpatient safety: resuscitation procedures and the monitoring technology used to detect patients who are in distress.

The inquiry has been examining the use of Oxevision, a system that employs infrared sensors and cameras to monitor patients while they are in their bedrooms. The technology can capture footage and record breathing and pulse rates, and it is currently used by a number of NHS mental health trusts across England. Its role in inpatient care has become a recurring theme in the evidence presented to the inquiry.

Concerns have been raised about whether such vision-based monitoring compromises patient privacy and dignity, and whether it might be used as a substitute for face-to-face care rather than as a supplement to it. Relatives of patients who died have voiced some of the strongest criticisms. Tammy Smith, whose daughter Sophie Alderman died in 2022, told the inquiry that the technology "actually takes away human interaction" at the point when patients are most vulnerable. She said patients need conversations and someone to ask whether they are alright or need anything, describing that need as universal.

The company behind Oxevision, LIO Health, has defended its product, stating that the technology helps prevent serious incidents, supports staff in delivering care and reduces the time clinicians spend on paperwork. NHS England has said that any vision-based monitoring technology must support a human rights-based approach to care and must be used in line with legal requirements and with appropriate patient consent.

Baroness Lampard stressed that the two matters under consideration are not specific to Essex, meaning the evidence gathered will be relevant to service providers nationwide. She noted that the findings "may carry implications for the care and treatment provided on all mental health units," suggesting the inquiry's reach could extend well beyond the county at the centre of the investigation.

The upcoming sessions, running from 5 to 15 October, will hear evidence from NHS England, the Care Quality Commission and the Medicines and Healthcare products Regulatory Agency. Their testimony is expected to shed light on how monitoring technologies and resuscitation practices are regulated and overseen across the health service. The hearings will take place at Chelmsford Civic Centre rather than in London, where previous sessions have been held, bringing the proceedings closer to the communities most affected.

After the October hearings, families will be invited to give their views on possible recommendations during a virtual hearing on 20 October. Baroness Lampard will then determine whether interim recommendations should be issued. This sequence gives bereaved relatives a direct opportunity to shape any early guidance before it is finalised.

The inquiry's final report is not expected until 2028. Its conclusions could have national implications for mental health services across England, particularly regarding how providers balance technological monitoring with compassionate, person-centred care. The prospect of interim recommendations reflects a recognition that some safety lessons may be too important to delay until the full report is complete.

For the families who have waited years for answers, the possibility of early findings offers a measure of hope that systemic problems identified in the evidence will be addressed before more lives are lost. The inquiry has already heard repeated testimony from relatives who believe their loved ones were failed by the system, and the focus on resuscitation and monitoring technology suggests the inquiry is examining the practical, everyday decisions that can determine whether a patient survives a crisis.

The decision to hold hearings in Chelmsford also signals an effort to keep the process accessible to those directly affected. Previous hearings in London drew protests from families demanding justice, with many holding photographs of their loved ones and signs calling for accountability.

As the inquiry prepares to resume, the central question is whether the evidence will persuade Baroness Lampard that urgent action is required. Any interim recommendations would carry weight not only in Essex but potentially across the entire country, setting expectations for how mental health units monitor, resuscitate and care for the people most at risk.